Welcome to our dedicated page for Establishment Labs Holdings news (Ticker: $ESTA), a resource for investors and traders seeking the latest updates and insights on Establishment Labs Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Establishment Labs Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Establishment Labs Holdings's position in the market.
Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced a securities purchase agreement with institutional accredited investors to purchase common shares or pre-funded warrants. Preliminary unaudited financial results for Q4 2023 show expected revenue in the range of $31.4 million to $31.8 million, in line with previous guidance. Full-year 2023 revenue is expected to be $165.0 million to $165.4 million, with a year-end cash position of approximately $39.1 million. The company will sell two million common shares or pre-funded warrants at $25.00 per share, expecting aggregate gross proceeds of approximately $50 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
-
Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that the Motiva Flora® SmoothSilk® Tissue Expander was used for the first time in the United States at the University of Texas MD Anderson Cancer Center in Houston by Mark Clemens, MD MBA FACS, Professor of Plastic Surgery. The recent FDA clearance and first procedure mark significant developments in the field of plastic and reconstructive surgery. The Flora® Tissue Expander includes several proprietary innovations, including Establishment Labs’ patented SmoothSilk® surface technology and an RFID-enabled, non-magnetic port, labeled as MR Conditional by the FDA. SmoothSilk® has been shown to produce the least amount of inflammation and foreign body response compared to other device surfaces. By being magnet-free, Flora avoids the interference that magnets cause during MRI and may improve the precision of radiation oncology treatment. Juan José Chacón-Quirós, Founder and CEO of Establishment Labs, emphasized the company's commitment to improving women’s health and wellness, stating that real innovation leads to better patient outcomes, and Flora is setting a new standard in breast reconstruction.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.7%
Tags
-
Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announces participation in the 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.38%
Tags
Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) announces participation in two investment conferences, including the 2023 Jefferies London Healthcare Conference and the Stephens Annual Investment Conference. CEO and Founder Juan José Chacón-Quirós and CFO Raj Denhoy will speak at the events, with live webcasts available on the company's investor relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.83%
Tags
-
Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) has received NMPA approval in China for Motiva® Implants, marking their entry into the second largest global market for breast aesthetics. The company expects Chinese plastic surgeons to adopt their technology as their first choice, based on their success in South Korea.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.32%
Tags
-
Rhea-AI Summary
Establishment Labs Holdings Inc. (NASDAQ: ESTA) Announces Q3 2023 Financial Results: Revenue Up 0.8%, 2023 Revenue Guidance Increased to $165 Million, Loss from Operations Increases, FDA Clearance for Motiva Flora® SmoothSilk® Tissue Expander, Mia Femtech™ Clinical Study Data Released
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.18%
Tags
Rhea-AI Summary
Flora, the magnet-free and MR Conditional tissue expander, has been cleared for the U.S. market. Establishment Labs Holdings Inc. plans to announce its financial results for Q3 2023 on November 7, 2023, and will host a conference call to discuss those results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
-
Rhea-AI Summary
Establishment Labs receives FDA clearance for Motiva Flora® SmoothSilk® Tissue Expander
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.25%
Tags
-
Rhea-AI Summary
Establishment Labs announces two-year clinical results of Mia Femtech and launch of Zen RFID technology
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.15%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.27%
Tags
Establishment Labs Holdings Inc.
Nasdaq:ESTA
ESTA Rankings
ESTA Stock Data
1.48B
16.31M
12.45%
75.8%
18.1%
Surgical and Medical Instrument Manufacturing
Manufacturing
United States of America
ALAJUELA
About ESTA
establishment labs is a global, privately held, high-tech medical device and aesthetics company that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast and body shaping implants. with more than 30 years of advanced breast implant manufacturing experience, building quality breast implants has always been a natural outcome for establishment labs’ founders and top executives. as a result, motiva implants® has established a level of product innovation that always results in safety. and while we respect our past, we ́re more focused on the present and the future, one that ́s innovative, safe and progressive. we believe that these goals can be achieved by incorporating the current needs and preferences of plastic surgeons and patients into our product design.